Welcome to the new version of CaltechAUTHORS. Login is currently restricted to library staff. If you notice any issues, please email coda@library.caltech.edu
Published March 3, 2020 | Supplemental Material + Published
Journal Article Open

Mixed Valvular Disease Following Transcatheter Aortic Valve Replacement: Quantification and Systematic Differentiation Using Clinical Measurements and Image-Based Patient‐Specific In Silico Modeling

Abstract

Background: Mixed valvular disease (MVD), mitral regurgitation (MR) from pre‐existing disease in conjunction with paravalvular leak (PVL) following transcatheter aortic valve replacement (TAVR), is one of the most important stimuli for left ventricle (LV) dysfunction, associated with cardiac mortality. Despite the prevalence of MVD, the quantitative understanding of the interplay between pre‐existing MVD, PVL, LV, and post‐TAVR recovery is meager. Methods and Results: We quantified the effects of MVD on valvular‐ventricular hemodynamics using an image‐based patient‐specific computational framework in 72 MVD patients. Doppler pressure was reduced by TAVR (mean, 77%; N=72; P<0.05), but it was not always accompanied by improvements in LV workload. TAVR had no effect on LV workload in 22 patients, and LV workload post‐TAVR significantly rose in 32 other patients. TAVR reduced LV workload in only 18 patients (25%). PVL significantly alters LV flow and increases shear stress on transcatheter aortic valve leaflets. It interacts with mitral inflow and elevates shear stresses on mitral valve and is one of the main contributors in worsening of MR post‐TAVR. MR worsened in 32 patients post‐TAVR and did not improve in 18 other patients. Conclusions: PVL limits the benefit of TAVR by increasing LV load and worsening of MR and heart failure. Post‐TAVR, most MVD patients (75% of N=72; P<0.05) showed no improvements or even worsening of LV workload, whereas the majority of patients with PVL, but without that pre‐existing MR condition (60% of N=48; P<0.05), showed improvements in LV workload. MR and its exacerbation by PVL may hinder the success of TAVR.

Additional Information

© 2020 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. Manuscript received October 23, 2019; Manuscript accepted January 9, 2020; Originally published February 28, 2020. Keshavarz‐Motamed and Khodaei were supported, in part, by Natural Sciences and Engineering Research Council (NSERC) Discovery Grant (RGPIN‐2017‐05349). Edelman was supported, in part, by a grant from the National Institutes of Health (GM R01 49039). Disclosures: Keshavarz‐Motamed has research grants from NSERC, but there is no overlap with the work in this study. Edelman has research grants from Edwards LifeSciences, Boston Scientific, and Medtronic, but there is no overlap with the work in this study. The remaining authors have no disclosures to report.

Attached Files

Published - JAHA.119.015063.pdf

Supplemental Material - jah34876-sup-0001-datas1.pdf

Files

JAHA.119.015063.pdf
Files (7.3 MB)
Name Size Download all
md5:b9280201f01c07a167882cba8ddd20a7
7.2 MB Preview Download
md5:d3ecd0a28b3a1f2fac0bfe1b420a350a
169.3 kB Preview Download

Additional details

Created:
August 22, 2023
Modified:
October 19, 2023